tiprankstipranks
Trending News
More News >
Privi Speciality Chemicals Limited (IN:PRIVISCL)
:PRIVISCL
India Market
Advertisement

Privi Speciality Chemicals Limited (PRIVISCL) AI Stock Analysis

Compare
0 Followers

Top Page

IN:PRIVISCL

Privi Speciality Chemicals Limited

(PRIVISCL)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 4o)
Rating:65Neutral
Price Target:
₹2,600.00
▼(-3.97% Downside)
Privi Speciality Chemicals Limited demonstrates strong financial performance with robust revenue growth and profitability. However, liquidity concerns due to negative free cash flow and a high P/E ratio indicating potential overvaluation weigh on the overall score. Technical indicators show a positive trend, supporting the stock's current momentum.

Privi Speciality Chemicals Limited (PRIVISCL) vs. iShares MSCI India ETF (INDA)

Privi Speciality Chemicals Limited Business Overview & Revenue Model

Company DescriptionPrivi Speciality Chemicals Limited operates as a manufacturer, supplier, and exporter of aroma and fragrance chemicals in India and internationally. It offers amber fleur, acetates, dihydromyrcenol, ionones, nitriles, sandal wood derivatives, and specialty chemicals, as well as bulk aroma chemicals; and nutraceutical products. The company also provides aroma chemicals, such as alpha damascone, alpha ionone, alpha terpenyl acetate, amber fleur, amber gamma, beta iso damascol, BI perfumery grade, BI technical grade, carene-60 & Carene-90, cedar ketol, citronellal, citronellyl acetate, citronellyl nitrile, dipentene, double distilled turpentine oil, dihydro myrcenol, dihydromyrcene, gamma methyl ionone, gamma terpenyl acetate, geraniol, geranyl acetate, Indian sandal core, ionone, iso boronyl acetate, l-limonene, methyl ionone, nerol, neryl acetate, nimberol, OTBCHA, pine oil, prionyl, PTBCHA, terpeniol alpha, terpeniol gamma, terpeniol MU &BP grade, terpinolene, sandal fleur, sandal touch, tetrahydroflorol, tetrahydrogeraniol, tetrahydrogeranyl acetate, tetrahydromyrcenol, timber forte, and timber touch. The company was formerly known as Fairchem Speciality Limited and changed its name to Privi Speciality Chemicals Limited in October 2020. Privi Speciality Chemicals Limited was incorporated in 1985 and is based in Mumbai, India.
How the Company Makes MoneyPrivi Speciality Chemicals Limited generates revenue primarily through the manufacture and sale of aroma and fragrance chemicals. The company's key revenue streams include direct sales to fragrance manufacturers, partnerships with consumer goods companies, and long-term supply agreements with major players in the personal care and household products industries. Privi's focus on research and development allows it to create specialized compounds that command higher value, thus contributing to its profitability. Additionally, the company may engage in strategic collaborations or joint ventures to expand its market reach and enhance its product portfolio, further driving its revenue growth.

Privi Speciality Chemicals Limited Financial Statement Overview

Summary
Privi Speciality Chemicals Limited shows strong revenue growth and profitability with a robust gross profit margin of 38.9% and a net profit margin of 8.9%. The balance sheet is solid with a debt-to-equity ratio of 1.04 and an ROE of 16.9%. However, the negative free cash flow due to high capital expenditures is a concern for liquidity.
Income Statement
75
Positive
Privi Speciality Chemicals Limited has demonstrated a robust revenue growth rate of 19.9% from 2024 to 2025, indicating strong demand and expansion. The gross profit margin stands at a healthy 38.9%, and the net profit margin improved to 8.9% in 2025, reflecting enhanced profitability. However, the EBIT margin is notably high at 34.7%, suggesting significant operational efficiency. EBITDA margin has decreased from the previous year but remains substantial at 21.4%. Overall, the company shows positive growth and profitability trends.
Balance Sheet
70
Positive
The debt-to-equity ratio is 1.04, showing a balanced leverage position, while the return on equity (ROE) improved to 16.9% in 2025, indicating effective utilization of equity capital. The equity ratio is stable at 39.5%, reflecting a sound capital structure. Despite a slight increase in debt levels, the company maintains a managed balance sheet with adequate equity backing its assets.
Cash Flow
65
Positive
Operating cash flow to net income ratio is 1.50, indicating strong cash generation relative to net earnings. However, the free cash flow has turned negative in 2025, primarily due to capital expenditures exceeding operating cash flows. The free cash flow to net income ratio is negative, highlighting potential liquidity constraints. Although operating cash flows are robust, the significant outflow for capital investments is a concern for free cash flow sustainability.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue21.96B21.01B17.52B16.08B14.04B12.77B
Gross Profit8.77B8.01B5.91B4.80B4.57B5.11B
EBITDA4.78B4.46B3.18B1.79B1.90B2.04B
Net Income2.18B1.87B949.07M222.15M973.80M1.17B
Balance Sheet
Total Assets0.0027.91B23.43B23.91B21.76B15.40B
Cash, Cash Equivalents and Short-Term Investments573.04M577.31M635.46M271.77M445.19M154.53M
Total Debt0.0011.43B10.08B10.79B9.30B5.37B
Total Liabilities-11.18B16.73B14.01B15.56B13.56B8.18B
Stockholders Equity11.18B11.03B9.24B8.29B8.12B7.23B
Cash Flow
Free Cash Flow0.00-180.27M2.04B-909.33M-3.04B-706.96M
Operating Cash Flow0.002.81B3.54B487.59M47.36M1.72B
Investing Cash Flow0.00-2.94B-1.80B-1.33B-3.20B-2.42B
Financing Cash Flow0.00386.33M-1.71B723.05M3.33B229.48M

Privi Speciality Chemicals Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2707.55
Price Trends
50DMA
2414.29
Positive
100DMA
2400.75
Positive
200DMA
2095.01
Positive
Market Momentum
MACD
70.24
Negative
RSI
67.89
Neutral
STOCH
89.08
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PRIVISCL, the sentiment is Positive. The current price of 2707.55 is above the 20-day moving average (MA) of 2481.68, above the 50-day MA of 2414.29, and above the 200-day MA of 2095.01, indicating a bullish trend. The MACD of 70.24 indicates Negative momentum. The RSI at 67.89 is Neutral, neither overbought nor oversold. The STOCH value of 89.08 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PRIVISCL.

Privi Speciality Chemicals Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
₹131.69B16.421.05%-0.65%7.37%
72
Outperform
₹28.17B27.040.65%-8.66%-17.79%
65
Neutral
₹106.75B49.070.18%21.50%78.82%
62
Neutral
₹98.53B52.780.52%10.29%26.09%
61
Neutral
$10.43B7.12-0.05%2.87%2.86%-36.73%
60
Neutral
₹79.50B50.480.62%-6.59%-41.72%
49
Neutral
₹99.41B128.030.36%103.52%-42.97%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:PRIVISCL
Privi Speciality Chemicals Limited
2,707.55
973.32
56.12%
IN:ACI
Archean Chemical Industries Ltd.
658.30
15.76
2.45%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,920.75
-244.87
-11.31%
IN:FCL
Fineotex Chemical Limited
244.75
-155.31
-38.82%
IN:NCC
NCC Limited
206.45
-93.90
-31.26%
IN:SUDARSCHEM
Sudarshan Chemical Industries Limited
1,240.95
231.74
22.96%

Privi Speciality Chemicals Limited Corporate Events

Privi Speciality Chemicals Declares No Share Encumbrances for FY 2025
Jun 29, 2025

Privi Speciality Chemicals Limited has announced that there were no encumbrances made on its equity shares by the promoter group during the financial year ending March 31, 2025. This disclosure under SEBI regulations ensures transparency and may positively impact stakeholder confidence, reinforcing the company’s stable financial positioning within the industry.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 04, 2025